Free Trial

Notable Labs Q1 2023 Earnings Report

Notable Labs Earnings Headlines

Notable Labs (NTBL) was downgraded to a Hold Rating at JMP Securities
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Notable Labs Announces CEO Transition
See More Notable Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Notable Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Notable Labs and other key companies, straight to your email.

About Notable Labs

Notable Labs (NASDAQ:NTBL), a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.

View Notable Labs Profile

More Earnings Resources from MarketBeat

Upcoming Earnings